尿毒症合并贫血患者输注悬浮红细胞和红细胞生成素疗效对比研究

The study on the comparison of therapeutic effects on the suspended red blood cell transfusion and erythropoietin of uremic patients with anemia

目的探讨输注悬浮红细胞和红细胞生成素两种方法对晚期尿毒症合并贫血患者生存质量改善的差异。方法对45例晚期尿毒症合并贫血患者随机分为输注悬浮红细胞治疗组(Ⅰ组)和红细胞生成素治疗组(Ⅱ组),比较两组患者生存质量改善的差异。结果在Ⅰ组和Ⅱ组患者之间,体力水平和日常活动的改善几乎相似,差异无统计学意义(5.9±2.1vs5.3±2.3和7.5±2.4vs7.1±2.6,t=0.6和t=0.2,P>0.05)。但在Ⅱ组患者,总生存质量的改善显著优于Ⅰ组输注悬浮红细胞的患者,差异有统计学意义(11.5±3.4vs3.1±1.6,t=2.3,P<0.05)。结论输注悬浮红细胞和红细胞生成素对尿毒症合并贫血治疗均安全有效。

Objective To study the efficacy and safety of the interventional therapy to improve the quality of the life（QOL）of the uremic patients with anemia. Methods 45 uremic patients were randomly divided into transfu sion group（ Ⅰgroup）and erythropoietin（EPO）group（ Ⅱ group）. Results There was no remarkably difference as to the energy level and daily activity improvement between group Ⅰ and Ⅱ （5.9±2.1 vs 5.3±2.3 and 7.5±2.4 vs 7.1 ±2.6,t=0.6 and t=0.2,P〈0.05）. But overall QOL was significantly increased in the patients of Group Ⅱ,compared with the patients using conventional transfusion method（11.5± 3.4 vs 3.1± 1.6,t= 2.3, P〈0.05. Conclusion Both transfusion and erythropoietin therapy could besafe to the patients and can improve QOL of uremic patients with anemia.